Myriad Genetics to Announce Quarterly Financial Results on November 9, 2020

Rhea-AI Summary

Myriad Genetics, Inc. (NASDAQ: MYGN) has announced its quarterly earnings conference call for the period ending September 30, 2020, scheduled for 5 p.m. EST on November 9, 2020. Key executives, including CEO Paul J. Diaz and CFO R. Bryan Riggsbee, will discuss the company's financial performance and business updates during the call. Investors can join via a dedicated conference line or through a live webcast available on Myriad's official website. This call will provide insights into the company's financial metrics and strategic direction.

Positive

• Scheduled earnings call indicates transparency and communication with investors.
• Potential for positive updates on financial performance discussed during the call.

Negative

• No specific financial metrics or guidance provided in the PR.
• Lack of detailed information may limit investor insights prior to the call.

SALT LAKE CITY, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its quarterly earnings conference call for the period ending September 30, 2020 with investors and analysts at 5 p.m. EST on Monday, November 9, 2020. During the call, Paul J. Diaz, president and CEO, and R. Bryan Riggsbee, chief financial officer, will provide a financial overview and business update of Myriad’s performance for the quarter. 

The dial-in number for domestic callers is 1-800-760-5095. International callers may dial 1-212-231-2937. All callers will be asked to reference reservation number 21970797. An archived replay of the call will be available for seven days by dialing 1-800-633-8284 and entering the reservation number above. The conference call along with a slide presentation will be available through a live webcast at www.myriad.com.

About Myriad Genetics
Myriad Genetics, Inc. is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. For more information, visit the company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Media Contact:	Jared Maxwell		Investor Contact:	Scott Gleason
	(801) 505-5027			(801) 584-1143
	jmaxwell@myriad.com			sgleason@myriad.com

FAQ

When is Myriad Genetics' earnings call for the third quarter of 2020?

Myriad Genetics' earnings call is scheduled for 5 p.m. EST on November 9, 2020.

Who will be presenting during the Myriad Genetics earnings call?

CEO Paul J. Diaz and CFO R. Bryan Riggsbee will present during the earnings call.

How can I listen to the Myriad Genetics earnings call?

You can listen to the earnings call via the conference call number or through a live webcast on the Myriad Genetics website.

What financial period does Myriad Genetics' upcoming earnings call cover?

The earnings call covers the financial results for the period ending September 30, 2020.

What type of updates can investors expect during the Myriad Genetics earnings call?

Investors can expect a financial overview and business update regarding Myriad's performance for the quarter.